Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice

Lutz E Pillunat,1 Peter Eschstruth,2 Stefan Häsemeyer,3 Ulrich Thelen,4 Christian Foja,5 Richard Leaback,6 Stefan Pfennigsdorf7 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Ophthalmology Practice, Kiel, 3Eye Center Kraichgau, Wiesloch, 4Department of Ophth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pillunat LE, Eschstruth P, Häsemeyer S, Thelen U, Foja C, Leaback R, Pfennigsdorf S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	bimatoprost 0.03% intraocular pressure prostaglandin preservative-free benzalkonium chloride-free Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6da8ae26f416443db501a75c0ffe621b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6da8ae26f416443db501a75c0ffe621b
record_format	dspace
spelling	oai:doaj.org-article:6da8ae26f416443db501a75c0ffe621b2021-12-02T01:00:08ZPreservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice1177-5483https://doaj.org/article/6da8ae26f416443db501a75c0ffe621b2016-09-01T00:00:00Zhttps://www.dovepress.com/preservative-free-bimatoprost-003-in-patients-with-primary-open-angle--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Lutz E Pillunat,1 Peter Eschstruth,2 Stefan Häsemeyer,3 Ulrich Thelen,4 Christian Foja,5 Richard Leaback,6 Stefan Pfennigsdorf7 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Ophthalmology Practice, Kiel, 3Eye Center Kraichgau, Wiesloch, 4Department of Ophthalmology, University of Münster, Münster, 5Ophthalmology Practice, Leipzig, Germany; 6Allergan Holdings Ltd., Marlow, UK; 7Ophthalmology Practice, Polch, Germany Background: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting. Methods: This open-label study observed patients who were switched to PF bimatoprost 0.03% for medical reasons. IOP was measured at baseline and ~12 weeks later at the final visit, and the change in IOP was calculated. Tolerability and continuation of therapy were assessed at two follow-up visits. Results: A total of 1,830 patients were included in the study, and complete IOP data were available for 1,543 patients. Mean IOP was reduced by 23% from 21.64 mmHg to 16.59 mmHg (P<0.0001). In subgroup analyses, the mean IOP was significantly reduced compared with baseline, regardless of prior therapy, including those previously treated with PF monotherapy. A total of 85.7% of physicians reported the IOP-lowering efficacy of PF bimatoprost 0.03% to be as expected or better than expected. Adverse events (AEs) were experienced by 5.7% of patients, and there were no serious AEs reported. The most common AEs were eye irritation (1.7%) and hyperemia (1.4%). Physician-reported treatment compliance was reported as better than (48.7%) or equal to (43.6%) prior treatment in most patients. Most patients (82%) were expected to continue PF bimatoprost 0.03% after the end of the study. Conclusion: This observational study showed that, in clinical practice, switching to PF bimatoprost 0.03% was associated with a significant IOP reduction from baseline. There was a low AE rate. PF bimatoprost 0.03% may, therefore, be an effective treatment option for patients who are intolerant of preservatives or have an inadequate response to prior IOP-lowering treatments. Keywords: bimatoprost 0.03%, intraocular pressure, prostaglandin, preservative free, benzalkonium chloride freePillunat LEEschstruth PHäsemeyer SThelen UFoja CLeaback RPfennigsdorf SDove Medical Pressarticlebimatoprost 0.03%intraocular pressureprostaglandinpreservative-freebenzalkonium chloride-freeOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 10, Pp 1759-1765 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	bimatoprost 0.03% intraocular pressure prostaglandin preservative-free benzalkonium chloride-free Ophthalmology RE1-994
spellingShingle	bimatoprost 0.03% intraocular pressure prostaglandin preservative-free benzalkonium chloride-free Ophthalmology RE1-994 Pillunat LE Eschstruth P Häsemeyer S Thelen U Foja C Leaback R Pfennigsdorf S Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
description	Lutz E Pillunat,1 Peter Eschstruth,2 Stefan Häsemeyer,3 Ulrich Thelen,4 Christian Foja,5 Richard Leaback,6 Stefan Pfennigsdorf7 1Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, 2Ophthalmology Practice, Kiel, 3Eye Center Kraichgau, Wiesloch, 4Department of Ophthalmology, University of Münster, Münster, 5Ophthalmology Practice, Leipzig, Germany; 6Allergan Holdings Ltd., Marlow, UK; 7Ophthalmology Practice, Polch, Germany Background: Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting. Methods: This open-label study observed patients who were switched to PF bimatoprost 0.03% for medical reasons. IOP was measured at baseline and ~12 weeks later at the final visit, and the change in IOP was calculated. Tolerability and continuation of therapy were assessed at two follow-up visits. Results: A total of 1,830 patients were included in the study, and complete IOP data were available for 1,543 patients. Mean IOP was reduced by 23% from 21.64 mmHg to 16.59 mmHg (P<0.0001). In subgroup analyses, the mean IOP was significantly reduced compared with baseline, regardless of prior therapy, including those previously treated with PF monotherapy. A total of 85.7% of physicians reported the IOP-lowering efficacy of PF bimatoprost 0.03% to be as expected or better than expected. Adverse events (AEs) were experienced by 5.7% of patients, and there were no serious AEs reported. The most common AEs were eye irritation (1.7%) and hyperemia (1.4%). Physician-reported treatment compliance was reported as better than (48.7%) or equal to (43.6%) prior treatment in most patients. Most patients (82%) were expected to continue PF bimatoprost 0.03% after the end of the study. Conclusion: This observational study showed that, in clinical practice, switching to PF bimatoprost 0.03% was associated with a significant IOP reduction from baseline. There was a low AE rate. PF bimatoprost 0.03% may, therefore, be an effective treatment option for patients who are intolerant of preservatives or have an inadequate response to prior IOP-lowering treatments. Keywords: bimatoprost 0.03%, intraocular pressure, prostaglandin, preservative free, benzalkonium chloride free
format	article
author	Pillunat LE Eschstruth P Häsemeyer S Thelen U Foja C Leaback R Pfennigsdorf S
author_facet	Pillunat LE Eschstruth P Häsemeyer S Thelen U Foja C Leaback R Pfennigsdorf S
author_sort	Pillunat LE
title	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
title_short	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
title_full	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
title_fullStr	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
title_full_unstemmed	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
title_sort	preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/6da8ae26f416443db501a75c0ffe621b
work_keys_str_mv	AT pillunatle preservativefreebimatoprost003inpatientswithprimaryopenangleglaucomaorocularhypertensioninclinicalpractice AT eschstruthp preservativefreebimatoprost003inpatientswithprimaryopenangleglaucomaorocularhypertensioninclinicalpractice AT hasemeyers preservativefreebimatoprost003inpatientswithprimaryopenangleglaucomaorocularhypertensioninclinicalpractice AT thelenu preservativefreebimatoprost003inpatientswithprimaryopenangleglaucomaorocularhypertensioninclinicalpractice AT fojac preservativefreebimatoprost003inpatientswithprimaryopenangleglaucomaorocularhypertensioninclinicalpractice AT leabackr preservativefreebimatoprost003inpatientswithprimaryopenangleglaucomaorocularhypertensioninclinicalpractice AT pfennigsdorfs preservativefreebimatoprost003inpatientswithprimaryopenangleglaucomaorocularhypertensioninclinicalpractice
_version_	1718403390506008576

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice

Ejemplares similares